The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.
The prognostic impact of TP53 mutation on survival outcomes in ALK fusion–positive lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials Between August ...
Introduction Skin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment ...
New EGFR-targeting combos may improve response rates and durability for patients with head and neck cancer.
Brain metastases remain a defining challenge in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer ...
Nearly 40 years ago, researchers identified the epidermal growth factor (EGF) domain as a key component in mussel adhesive proteins. Since then, similar adhesive proteins have been discovered in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results